Dynamics of HbA1c, BMI and rates of severe hypoglycemia in 4,434 adults with type 1 or type 2 diabetes after initiation of continuous glucose monitoring.

Lanzinger, Stefanie; Best, Frank; Bergmann, Tanja; Laimer, Markus; Lipovsky, Boris; Danne, Thomas; Zimny, Stefan; Bramlage, Peter; Meyhöfer, Svenja; Holl, Reinhard W (2022). Dynamics of HbA1c, BMI and rates of severe hypoglycemia in 4,434 adults with type 1 or type 2 diabetes after initiation of continuous glucose monitoring. Diabetes technology & therapeutics, 24(10), pp. 763-769. Mary Ann Liebert 10.1089/dia.2022.0063

[img]
Preview
Text
dia.2022.0063.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (816kB) | Preview

BACKGROUND

Continuous glucose monitoring (CGM) might have beneficial effects on glycemic control and body-mass-index (BMI) in adults with type 1 (T1D) or type 2 diabetes (T2D).

METHODS

The diabetes prospective follow-up registry was used to identify individuals with T1D or T2D ≥18 years starting CGM management in 2015 or later and follow-up information available. HbA1c, BMI and event rates of severe hypoglycemia in the year prior to CGM start were compared to two follow-up periods: 1) CGM use for 3-6 months and 2) CGM use for >6 months. Repeated measurements linear and negative binomial regression were used (adjustment for sex, age at diabetes onset and baseline parameters) and stratified by diabetes type.

RESULTS

Mean follow-up time was 1.8 years in T1D (n=2,994) and 1.9 years in T2D (n=1,440). In T1D, adjusted mean HbA1c decreased significantly from 7.65% (95%-confidence interval: 7.62-7.68) at baseline to 7.54% (7.51-7.57) during follow-up. BMI increased slightly (baseline: 25.4 kg/m2 (25.3-25.5), follow-up >6 months: 25.8 kg/m2 (25.7-25.9)), whereas event rates of severe hypoglycemia were significantly lower after >6 months with CGM (9.0 events/100 PY (8.0-10.1)) compared to baseline (11.3 events/100 PY (10.4-12.2)) in adults with T1D. In T2D, HbA1c decreased from 7.21% (7.17-7.25) to 7.00% (6.95-7.04%) and BMI did not change after CGM initiation.

CONCLUSION

Our results provide real world evidence on CGM management in adult individuals with T1D or T2D. We suggest to strengthen patients' and physicians' readiness towards diabetes technology in T2D and more openness of health insurance to cover cost based on proven benefits.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition

UniBE Contributor:

Laimer, Markus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1520-9156

Publisher:

Mary Ann Liebert

Language:

English

Submitter:

Pubmed Import

Date Deposited:

03 Jun 2022 09:40

Last Modified:

04 Jun 2023 00:25

Publisher DOI:

10.1089/dia.2022.0063

PubMed ID:

35653726

BORIS DOI:

10.48350/170426

URI:

https://boris.unibe.ch/id/eprint/170426

Actions (login required)

Edit item Edit item
Provide Feedback